Former FDA Commissioners Criticized Staffing Cuts
The agency has begun efforts to rebuild its workforce after losing 3,500 employees due to government-led efficiency initiatives.
Updated on Oct. 14, 2026 in People
Live Poll
Do you trust that federal health agencies are making decisions free from political influence?
Three former FDA commissioners warned that recent federal staffing cuts have hindered the agency's operational capacity. The FDA has initiated a rehiring process to mitigate the loss of institutional knowledge following the departure of 3,500 staff members.
Why it matters
The loss of personnel and expertise risks destabilizing agency oversight and policy consistency. Former officials argue that restoration of the workforce is essential to shielding regulatory processes from external political pressure.
The agency saw a reduction of 3,500 workers implemented by the Department of Government Efficiency. The effort to regain institutional memory is currently underway, though the scope of the rehiring remains subject to budgetary and political factors.
The players
Marty Makary
The former FDA commissioner who resigned from the agency in May 2026.
Heidi Overton
The nominee for FDA commissioner currently awaiting a Senate confirmation vote.
Kyle Diamantas
The acting FDA commissioner responsible for navigating the agency through current staffing constraints.
Department of Government Efficiency
A federal initiative led by Elon Musk tasked with implementing government-wide staffing cuts.
The details
The staffing cuts, executed under the Elon Musk-led Department of Government Efficiency, left a significant void in the agency's regulatory expertise. The FDA is now attempting to reverse this trend by rehiring personnel to handle drug and device oversight. The transition remains delicate as Acting Commissioner Kyle Diamantas manages the agency while nominee Heidi Overton awaits a Senate confirmation vote.
Timeline
May 2026: Former FDA Commissioner Marty Makary resigned from his post.
2025: The FDA issued safety warnings regarding mRNA Covid-19 vaccines and heart inflammation.
October 14, 2026: Former FDA commissioners addressed the staffing impacts during a panel at the STAT Summit in Boston.
Market Landscape
The current efforts to rebuild the FDA follow a period of aggressive workforce reduction mandated by the Department of Government Efficiency. This cycle marks a departure from traditional federal staffing models, highlighting the volatility of regulatory oversight under shifting administrative priorities.
Operators in the medical and pharmaceutical sectors should anticipate potential delays in regulatory filings and policy updates as the agency works to restore staffing levels. Businesses should maintain close communication with their regulatory counsel to track shifts in agency leadership and enforcement priorities.
The takeaway
The agency's attempt to recover institutional knowledge emphasizes the ongoing instability within federal oversight bodies. Businesses should monitor the upcoming Senate confirmation process for the new commissioner as a primary indicator of future regulatory stability.
Further reading
For more on the individuals shaping current regulatory frameworks, visit the People section.
Source note: This article includes information reported by STAT.
Live Poll
Do you trust that federal health agencies are making decisions free from political influence?
